JP2006524243A5 - - Google Patents

Download PDF

Info

Publication number
JP2006524243A5
JP2006524243A5 JP2006509825A JP2006509825A JP2006524243A5 JP 2006524243 A5 JP2006524243 A5 JP 2006524243A5 JP 2006509825 A JP2006509825 A JP 2006509825A JP 2006509825 A JP2006509825 A JP 2006509825A JP 2006524243 A5 JP2006524243 A5 JP 2006524243A5
Authority
JP
Japan
Prior art keywords
use according
animal
syndrome
cognitive
training
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006509825A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006524243A (ja
JP4833834B2 (ja
Filing date
Publication date
Priority claimed from US10/410,508 external-priority patent/US20040224316A1/en
Application filed filed Critical
Publication of JP2006524243A publication Critical patent/JP2006524243A/ja
Publication of JP2006524243A5 publication Critical patent/JP2006524243A5/ja
Application granted granted Critical
Publication of JP4833834B2 publication Critical patent/JP4833834B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006509825A 2003-04-08 2004-04-08 増強認知訓練 Expired - Fee Related JP4833834B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/410,508 2003-04-08
US10/410,508 US20040224316A1 (en) 2000-08-10 2003-04-08 Augmented cognitive training
PCT/US2004/010876 WO2004091609A2 (en) 2001-08-10 2004-04-08 Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit

Publications (3)

Publication Number Publication Date
JP2006524243A JP2006524243A (ja) 2006-10-26
JP2006524243A5 true JP2006524243A5 (enExample) 2011-03-24
JP4833834B2 JP4833834B2 (ja) 2011-12-07

Family

ID=37416211

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006509825A Expired - Fee Related JP4833834B2 (ja) 2003-04-08 2004-04-08 増強認知訓練

Country Status (7)

Country Link
US (2) US20040224316A1 (enExample)
EP (4) EP2116240B1 (enExample)
JP (1) JP4833834B2 (enExample)
AT (1) ATE556707T1 (enExample)
CA (1) CA2521839C (enExample)
ES (3) ES2509093T3 (enExample)
WO (1) WO2004091609A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8153646B2 (en) 2000-08-10 2012-04-10 Dart Neuroscience (Cayman) Ltd. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
EP1355669B1 (en) 2000-08-10 2011-09-28 Cold Spring Harbor Laboratory Augmented cognitive training
US7868015B2 (en) 2000-08-10 2011-01-11 Cold Spring Harbor Laboratory Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit
US9931318B2 (en) 2003-04-08 2018-04-03 Dart Neuroscience (Cayman) Ltd. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
US8975216B2 (en) * 2006-03-30 2015-03-10 Pacific Biosciences Of California Articles having localized molecules disposed thereon and methods of producing same
EP2377533A3 (en) * 2006-05-19 2012-02-22 Helicon Therapeutics, Inc. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
TW200909417A (en) * 2007-03-12 2009-03-01 Biolipox Ab Piperidinones useful in the treatment of inflammation
GB0722769D0 (en) * 2007-11-21 2008-01-02 Biolipox Ab New compounds
AU2008254907A1 (en) * 2007-05-15 2008-11-27 Helicon Therapeutics, Inc. Methods of identifying genes involved in memory formation using small interfering RNA(siRNA)
BRPI0811625A2 (pt) * 2007-05-15 2014-11-11 Helicon Therapeutics Inc Métodos de tratamento de distúrbios cognitivos através da inibição da gpr12
JP5049713B2 (ja) * 2007-09-14 2012-10-17 株式会社コナミデジタルエンタテインメント ゲームシステム並びにこれを構成するゲーム装置及び課題報知装置
EP2313098A4 (en) * 2008-07-18 2011-12-21 Dart Neuroscience Llc METHOD AND SYSTEMS FOR THE ASSESSMENT OF MEMORY-PROMOTING ACTIVE SUBSTANCES
WO2011114103A1 (en) 2010-03-18 2011-09-22 Biolipox Ab Pyrimidinones for use as medicaments
US20150050626A1 (en) * 2013-03-15 2015-02-19 Dart Neuroscience, Llc Systems, Methods, and Software for Improving Cognitive and Motor Abilities
US20170119775A1 (en) * 2014-03-28 2017-05-04 Algiax Pharmaceuticals Gmbh Treatment of cognitive disorders
JP2017141222A (ja) * 2016-02-09 2017-08-17 国立大学法人帯広畜産大学 パーキンソン病に併発した認知障害の治療剤及びそのスクリーニング方法
WO2022156727A1 (zh) 2021-01-21 2022-07-28 浙江养生堂天然药物研究所有限公司 治疗肿瘤的组合物及方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5479508A (en) * 1991-05-22 1995-12-26 Zenith Electronics Corp. Method of operating a pay per view television system
US5547979A (en) * 1992-03-30 1996-08-20 Smithkline Beecham TNF inhibition
MX9301943A (es) 1992-04-02 1994-08-31 Smithkline Beecham Corp Compuestos.
AU678158B2 (en) 1992-04-10 1997-05-22 Fox Chase Cancer Center Transcription control element for increasing gene expression in myoblasts
CN1043993C (zh) * 1994-08-29 1999-07-07 山之内制药株式会社 萘啶衍生物及其医药组合物
US5619249A (en) * 1994-09-14 1997-04-08 Time Warner Entertainment Company, L.P. Telecasting service for providing video programs on demand with an interactive interface for facilitating viewer selection of video programs
MX9702518A (es) 1994-10-07 1998-02-28 Cold Spring Harbor Lab Clonaje y caracterizacion de genes asociados a la memoria a largo plazo.
US5929223A (en) * 1994-10-07 1999-07-27 Cold Spring Harbor Laboratory Cloning and characterizing of genes associated with long-term memory
US5652749A (en) * 1995-02-03 1997-07-29 International Business Machines Corporation Apparatus and method for segmentation and time synchronization of the transmission of a multiple program multimedia data stream
US5793410A (en) * 1995-05-26 1998-08-11 Hyundai Electronics America Video pedestal network
US5801030A (en) 1995-09-01 1998-09-01 Genvec, Inc. Methods and vectors for site-specific recombination
EP0936923B1 (en) * 1996-11-15 2003-12-17 Kennedy Institute Of Rheumatology SUPPRESSION OF TNFalpha AND IL-12 IN THERAPY
HUP0001541A3 (en) * 1997-01-15 2001-11-28 Altana Pharma Ag Phthalazinone derivatives and pharmaceutical compositions containing them
EP1112262B1 (en) 1998-09-09 2004-08-04 Inflazyme Pharmaceuticals Ltd. Substituted gamma-phenyl-delta-lactones and analogs thereof and uses related thereto
IT1303272B1 (it) 1998-10-29 2000-11-06 Zambon Spa Derivati triciclici inibitori della fosfodiesterasi 4
WO2000050402A1 (en) 1999-02-25 2000-08-31 Merck Frosst Canada & Co. Pde iv inhibiting compounds, compositions and methods of treatment
US6436965B1 (en) 2000-03-02 2002-08-20 Merck Frosst Canada & Co. PDE IV inhibiting amides, compositions and methods of treatment
US6555572B2 (en) 2000-03-16 2003-04-29 Inflazyme Pharmaceuticals Ltd. Benzylated PDE4 inhibitors
EP1355669B1 (en) * 2000-08-10 2011-09-28 Cold Spring Harbor Laboratory Augmented cognitive training
AU2003258287A1 (en) * 2002-08-19 2004-03-03 Helicon Therapeutics, Inc. Screening methods for cognitive enhancers

Similar Documents

Publication Publication Date Title
JP2006524243A5 (enExample)
Beaudin et al. Impact of obstructive sleep apnoea and intermittent hypoxia on cardiovascular and cerebrovascular regulation
Hays et al. The timing and amount of vagus nerve stimulation during rehabilitative training affect poststroke recovery of forelimb strength
JP2019031502A5 (enExample)
WO2004026246A3 (en) Methods of treating age associated memory impairment (aami), mild cognitive impairment (mci), and dementias with cell cycle inhibitors
EA200700427A1 (ru) Предупреждение и лечение синуклеинопатических и амилоидогенных заболеваний
Bernardes et al. Comprehensive catwalk gait analysis in a chronic model of multiple sclerosis subjected to treadmill exercise training
CA3020500A1 (en) Use of cannabidivarin in the treatment of autism spectrum disorder, associated disorders and schizophrenia
Guercio et al. Improving cognitive training for schizophrenia using neuroplasticity enhancers: lessons from decades of basic and clinical research
Wallingford et al. Increases in mature brain-derived neurotrophic factor protein in the frontal cortex and basal forebrain during chronic sleep restriction in rats: possible role in initiating allostatic adaptation
ATE424824T1 (de) Verfahren zur verhütung oder behandlung von herzarrhythmie
JP5517925B2 (ja) パーキンソン病治療薬
DE602005025347D1 (de) Oligoribonukleotide und verfahren zu deren anwendung bei der behandlung von fibrotischen leiden und anderen krankheiten
JP2010531862A (ja) パーキンソン病治療薬
Tellez et al. Autoradiographic study of serotonin transporter during memory formation
Badran et al. Recovery Mimicking “Ideal” CPAP Adherence Does Not Improve Wakefulness or Cognition in Chronic Murine Models of OSA: Effect of Wake-Promoting Agents
ATE429216T1 (de) Alpha 2b oder 2b/2c adrenozeptor-agonisten zur behandlung von morbus alzheimer und morbus parkinson
Dringenberg et al. Increased effectiveness of tacrine by deprenyl co-treatment in rats: EEG and behavioral evidence
JP2006504741A5 (enExample)
Li et al. Nicotinic acetylcholine signaling is required for motor learning but not for rehabilitation from spinal cord injury
JPWO2019157273A5 (enExample)
ATE432070T1 (de) Herabgesetzte dosis von tolterodin zur behandlung von harnwegserkrankungen
Mattson Exercise and the brain: a slap on the HAND
Melloni et al. Safinamide and glutamate release: new insights
EA200801278A1 (ru) Способ коррекции функциональных расстройств организма человека